Synovial sarcomas usually metastasize after >5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors.
about
Synovial sarcoma of the abdominal wall: Imaging findings and review of the literatureHDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial SarcomaWhat is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients.Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma: A SEER analysis.Primary pulmonary synovial sarcoma: a case report with unique and impressive computed tomography findings.The Role of (18)F-FDG PET/CT as a Prognostic Factor in Patients with Synovial SarcomaSS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.Synovial sarcoma in patients under 20 years of age: a multicenter study with a minimum follow-up of 10 years.[Head and neck synovial sarcoma: a rare location: report of two cases].Distinct Clinical Characteristics of Unplanned Excision in Synovial Sarcoma.Next generation sequencing in synovial sarcoma reveals novel gene mutations.Diagnostic Approach to Synovial Sarcoma of the Head and Neck Illustrated by Two Cases Arising in the Face and Oral Cavity.Primary pleuropulmonary and mediastinal synovial sarcoma: a clinicopathologic and molecular study of 26 genetically confirmed cases in the largest institution of southwest ChinaExpression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcomaFunctional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma.Metastatic biomarkers in synovial sarcoma.Prognostic value of SS18-SSX fusion type in synovial sarcoma; systematic review and meta-analysis.Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.Trabectedin is a promising antitumour agent for synovial sarcoma.A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway.The influential role of BCL2 family members in synovial sarcomagenesis.Prognosis of T1 synovial sarcoma depends upon surgery by oncologic surgeons.Identifying prognostic indicators in staging metastatic sarcomas using hospital episode statistics.Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.Prognostic factors and clinical outcomes in synovial sarcoma of the extremities.Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines.Enhancer of zeste homologue 2 (EZH2) expression in synovial sarcomas as a promising indicator of prognosis.Synovial sarcoma of the shoulder: A series of 14 cases.Synovial sarcoma showing loss of a green signal in SS18 fluorescence in situ hybridization: a clinicopathological and molecular study of 12 cases.Tibial adamantinoma: late metastasis to the brain.Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.Systemic Treatment for Adults with Synovial Sarcoma.Risk Factors Including Age, Stage and Anatomic Location that Impact the Outcomes of Patients with Synovial Sarcoma.
P2860
Q26863656-BA85D8D9-FBA3-4DD8-9266-DA6C82878035Q28468451-27C11880-49E0-4931-80AD-C2D7BE840742Q33613689-5CF747DD-A4E2-4475-9484-8ECFB0DBB71CQ33696791-F75B62D5-0026-4309-8A54-AAACA40F652FQ34664193-1A66F7A2-F907-4079-8C04-7EF9C57E56B8Q35073146-4366A171-9D40-47AD-98CC-EA4D0ABAB83AQ35162720-FCD614AF-8B86-4AE1-BE73-2FCF095E1CA7Q35200425-2CC2ACD1-505C-42ED-878A-FC8F31C3F693Q35230631-53D46DCE-8D03-4FF0-A24C-8CF9E0E394FEQ35787598-4FD78D5E-C4B8-444E-B0EE-9C14DC48F8E0Q35890300-59504101-74E0-4178-8A9E-7AD5948DD166Q36544186-570177CA-5655-4CB5-B82A-995B3F43E6ABQ36906350-728A6D6A-305B-4DE3-9A51-1A494394C7F4Q37082063-78E86D8E-B10C-4204-9EB9-C9356E107597Q37379626-7C23C3E1-DF23-4E7C-BA07-02A410E4BB59Q37544362-FB0B6446-6D54-4FED-B329-A3D791DE086EQ37630943-69861748-8A8D-47A9-97B0-0A4B045F03BEQ38555958-B58AED61-5044-49D3-BF49-E33F298761AEQ38567366-65A5F7B1-DF36-47E8-84F9-03CDE57F62DAQ38778290-BD7BA599-2AC0-4A1B-BA2B-F516E354E843Q39391651-E71439E9-EC54-491F-89DA-3BE0D89CE286Q40066050-B1F4E53E-59A2-4228-AAE2-0334A74AB98CQ40738166-882E51A4-7443-4EDA-ACBC-85BC0557AB47Q41005858-9A3D2426-53B6-431F-93BD-FA6BE0516BAEQ43432645-9021F89E-73DF-4D45-B9A8-A7BF308ED1F9Q43918357-A083151E-2421-4F01-B7FE-E829D4DCEAB6Q44948239-69AAF515-3899-4D94-8BD2-ED0F1CB197F9Q47158897-F5ADC679-E042-4608-883E-62CF14BBE928Q47428660-2B1980EB-61BF-4DD4-A1CB-D2FF44AF915CQ48005812-C4BA0915-B44B-4E02-8004-F607F0E8775FQ48425259-DA30475D-BEF0-4D89-9410-A213E61C3732Q52579552-B538956F-8026-4432-9399-9EFD1F91A2BEQ52667763-924B8282-9087-4BD0-A4A9-B7D260B4CDC5Q55260657-5668ED9F-E650-49A5-A97D-D6F335030F3F
P2860
Synovial sarcomas usually metastasize after >5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Synovial sarcomas usually meta ...... -up of 10 years for survivors.
@ast
Synovial sarcomas usually meta ...... -up of 10 years for survivors.
@en
Synovial sarcomas usually meta ...... -up of 10 years for survivors.
@nl
type
label
Synovial sarcomas usually meta ...... -up of 10 years for survivors.
@ast
Synovial sarcomas usually meta ...... -up of 10 years for survivors.
@en
Synovial sarcomas usually meta ...... -up of 10 years for survivors.
@nl
prefLabel
Synovial sarcomas usually meta ...... -up of 10 years for survivors.
@ast
Synovial sarcomas usually meta ...... -up of 10 years for survivors.
@en
Synovial sarcomas usually meta ...... -up of 10 years for survivors.
@nl
P2093
P2860
P356
P1433
P1476
Synovial sarcomas usually meta ...... w-up of 10 years for survivors
@en
P2093
A R von Hochstetter
E Mouhsine
F M Klenke
K A Siebenrock
P2860
P304
P356
10.1093/ANNONC/MDQ394
P577
2010-08-17T00:00:00Z